Amazon.com Inc vs Davita Inc — how do they compare? Amazon.com Inc trades at $273.19 (market cap $2.94T), while Davita Inc trades at $179.02 (market cap $11.38B). The key difference: Amazon.com Inc is far larger — about 258.3× Davita Inc's market cap, and Amazon.com Inc is trading nearer its 52-week high, Davita Inc nearer its low. Which is the better fit depends on your goals.
| AMZN | DVA | |
|---|---|---|
Market Cap | $2.94T | $11.38B |
Volume | 3,931,282 | — |
Sector | Consumer Cyclical | Health |
52-Week High | $284.02 | $240.96 |
52-Week Low | $198.79 | $103.87 |
Enterprise Value | $3.04T | $24.10B |
Signals from Pluang's Aura AI — not financial advice
Amazon (AMZN) trades at $278.09, up 1.32% with strong technical momentum and bullish moving averages. The company demonstrates robust fundamentals with revenue growth from $638B in 2024 to $716.9B in 2025 and net income surging to $77.7B. Recent earnings show beats in Q1 and Q2 2026, while analyst sentiment remains overwhelmingly positive with 89% buy ratings and a $333.86 consensus price target.
Amazon's outlook remains favorable with accelerating AI investments and AWS growth driving future cash flows. Key risks include aggressive capital expenditure plans ($216.8B investing outflow projected for 2026) and intensifying competition in e-commerce and cloud services. The stock presents growth potential but requires monitoring of execution on massive infrastructure investments.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Amazon.com, Inc. is an online retailer that offers a wide range of products. The Company products include books, music, computers, electronics and numerous other products. Amazon offers personalized shopping services, Web-based credit card payment, and direct shipping to customers. Amazon also operates a cloud platform offering services globally.
Read more on AMZN →DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →